Opinion|Videos|March 28, 2025
Clinical Attributes of IL-17 Inhibitors in Psoriasis
Panelists discuss how IL-17 inhibitors are biologics that target the inflammatory cytokine IL-17 pathway. They demonstrate rapid onset of action, with measurable improvement in most patients within 2 to 4 weeks and peak efficacy by 12 to 16 weeks. They achieve high rates of skin clearance in psoriasis patients and maintain efficacy with long-term use.
Advertisement
Episodes in this series
Video content above is prompted by the following:
What are some of the clinical attributes of IL-17 inhibitors? How quickly do they work in their onset of action, and how do they impact skin clearance?
Advertisement
Related to this article
Week 28 data from the phase 2a EVERLAST-A trial showed PASI 100 responses increased to 71.4% despite no additional ORKA-001 dosing after week 4.
Takeda’s investigational oral TYK2 inhibitor is supported by phase 3 LATITUDE data demonstrating significant skin clearance versus placebo and apremilast.
In a 52-week open-label trial, tildrakizumab-asmn (Ilumya) reduced a mortality-linked DNA methylation clock by up to 0.5 years while clearing psoriasis symptoms.
Advertisement
Advertisement
Trending on Dermatology Times
1
FAQ: Everything Clinicians (and Their Patients) Want to Know About the Hair Loss Pipeline
2
Barzolvolimab Achieves All Phase 3 End Points in Chronic Spontaneous Urticaria
3
ORKA-001 Achieves Deepening Skin Clearance Through Week 28 in Plaque Psoriasis
4
National APP Week: Donna Lam Cahill, PA-C, on Persistence, Patient Advocacy, and Finding a Career in Dermatology
5